The Medical Developments International Ltd (ASX: MVP) share price has been a strong performer on Thursday morning.
At the time of writing the healthcare company’s shares are up 5% to $6.33.
Why is the Medical Developments International share price charging higher?
Investors have been buying the company’s shares on Thursday after it provided an update on its key Penthrox product.
Penthrox is a fast onset, non-opioid analgesic indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. It has been around for decades in Australia and is better known by the public as the green whistle.
Over the last couple of years the company has successfully been expanding its presence globally, which leads us to today’s announcement.
This morning Medical Developments International announced that the Chinese National Medical Product Administration (NMPA) has approved the opening of the company’s Investigative New Drug (IND) application.
This application is a critical step to having Penthrox approved for sale in the massive China market.
According to the release, its submission in China is to have Penthrox approved for two separate indications – trauma pain and procedural pain.
Medical Developments International has commenced work to complete clinical bridging studies which are required in China for each indication. Management expects to complete them within 12 months. Furthermore, the company is undertaking a bridging Pharmacokinetic (PK) study.
These studies are designed to support the use of Penthrox in Chinese people and will be used as an adjunct to the global clinical data it has already submitted to the NMPA and other global authorities.
The company’s chairman, David Williams, described the Chinese IND as a “red letter day” for Medical Developments International. This sentiment was echoed by its CEO, John Sharman.
He said: “The approval of the Penthrox IND by the Chinese authorities is a significant milestone for our company. The NMPA has accepted the safety and efficacy of the global clinical data. The clinical program we are undertaking in China comprises small studies designed to support the safety and efficacy of Penthrox in Chinese people.”
“Our partner in China, Daiichi Sankyo, is Japan’s biggest pharmaceutical company, which is expanding aggressively in China. The Chinese market has an unmet need for a strong non opioid analgesic like Penthrox and the ultimate approval by the NMPA of Penthrox will be very positive for MVP and Daiichi Sankyo,” he added.
The post Medical Developments International shares surge higher on China news appeared first on Motley Fool Australia.
Looking for the next shares to charge higher? Then don't miss these high quality growth shares which have recently been tipped as buys.
Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.
One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…
Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield...
Plus 3 more cheap bets that could position you to profit over the next 12 months!
See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.
- Man bets $221,666 on one ASX stock
- Top analysts name their top 3 ASX blue chip shares for 2019
- 3 quality dividend shares to boost your income
- NEW: Free report names top 3 ASX dividend shares to buy for 2019
- 5 Stocks for Potentially Building Wealth After 50
James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.
The Motley Fool's purpose is to help the world invest, better. Click here now for your free subscription to Take Stock, The Motley Fool's free investing newsletter. Packed with stock ideas and investing advice, it is essential reading for anyone looking to build and grow their wealth in the years ahead. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 2019